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On-demand use of rabeprazole for the management of sympto-
matic GERD incurs the least cost in comparison to the other 
PPIs evaluated. Utility gains were comparable for all on-demand
PPIs.
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OBJECTIVES: To asses the cost-effectiveness of two initial man-
agement strategies for the general practitioner in dyspepsia. The
two strategies investigated are prompt endoscopy and a Heli-
cobacter pylori test-and-treat strategy. METHODS: Pharma-
coeconomic data was gathered alongside the SENSE (Strategy:
Endoscopy versus Serology)-study from 1998 up to 2001.
Patients were randomized in the endoscopy (n = 105) and test-
and-treat (n = 118) group. The costs were standardized costs for
1999. Quality of life was measured at inclusion and one year
later, using the validated Dutch translation of the RAND-36
questionnaire. The results obtained were transformed into one
overall score, in terms of Quality Adjusted Life Years (QALYs).
An incremental cost-effectiveness ratio (ICER) was calculated as
incremental cost of test-and-treat over early endoscopy per
QALY gained. For estimating the uncertainty we calculated 95%
uncertainty limits using parametric bootstrap with angular trans-
formation. RESULTS: For the test-and-treat group the total costs
per patient were 511.02€ and the number of QALYs gained was
0.074 per patient. For the endoscopy group this was 748.08€
and 0.064 QALYs gained. The point estimate of the ICER indi-
cated cost-savings and QALYs gained. Parametric bootstrap
uncertainty limits indicate cost-savings per QALY gained
(75.7%) and cost savings per QALY lost ranging from 11,970€
to inﬁnity. CONCLUSIONS: According to our data, the Heli-
cobacter test-and-treat strategy is more cost-effective than
prompt endoscopy in the initial management of dyspepsia in
general practice.
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OBJECTIVES: To compare the cost-effectiveness of esomepra-
zole versus pantoprazole and generic omeprazole from the per-
spective of the statutory health insurance using a decision model
reﬂecting naturalistic treatment behaviour in GERD patients in
Germany. METHODS: The model applies to patients with endo-
scopically veriﬁed GERD receiving PPI therapy and covers a
period of 8 weeks. Therapies included were esomeprazole 20 and
40mg, omeprazole 20 and 40mg and pantoprazole 40mg. Real-
life treatment patterns and resource utilization for acute and
maintenance treatment were derived from 30 physician inter-
views, whereas healing rates after 4 and 8 weeks of treatment
were derived from published literature. Resource utilization
included visits, examinations and laboratory tests at primary
care physicians and specialists, drug treatment of GERD, hospi-
talizations and working incapacity. RESULTS: Total costs per
patient ranged between 137€ for esomeprazole and 202€ for
pantoprazole with total healing rates after eight weeks between
85% (omeprazole) and 96% (esomeprazole). No hospitaliza-
tions were observed and the few sick leaves reported were shorter
than 42 days, inducing no costs from the insurance perspective.
Costs per patient healed varied between 145€ (esomeprazole)
and 218€ (pantoprazole), with most of the treatments ranging
closely around 200€. Due to the relatively small sample size, we
tested the robustness of the results by conducting sensitivity
analyses representing different degrees of standardization in
input parameters. Cost-effectiveness did not differ much in either
scenario; standardizing e.g. physician costs and treatment dura-
tion resulted in costs per patient healed between 163€ (esomepra-
zole) and 210€ (omeprazole). CONCLUSIONS: The results
indicate that esomeprazole is a cost-effective treatment option
for patients with endoscopically veriﬁed GERD treated over 8
weeks. Strongest competitor for esomeprazole is treatment with
generic omeprazole. The current model will be extended to a 6
month period as soon as the data from a currently completed
study will become available.
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OBJECTIVES: To analyze the cost-effectiveness of capsule
endoscopy (CE) in diagnosing obscure gastrointestinal bleeding
(OGIB) from a health care payer perspective in France, the UK,
and Switzerland. METHODS: Based on clinical trial data, a
microsimulation model incorporating ﬁrst- and second-order
Monte Carlo simulation was developed. The model calculates
the costs per correctly diagnosed case in patients with OGIB.
Sensitivity and speciﬁcity for CE and the comparator push
enteroscopy (PE) as well as kind and number of other procedures
performed prior to diagnosis were evaluated from 7 controlled
clinical trials (n = 184). Procedure cost, cost of diagnostic failure
(false positive/negative diagnosis) were considered and incre-
mental cost-effectiveness ratios dependent on disease prevalence
are given. Cost data were estimated from a healthcare payer per-
spective using the “Assurance Maladie” (France), NHS Refer-
ence Cost (UK), and the TARMED (Switzerland). RESULTS:
Sensitivity for CE was 89–99% and 27–60% for PE. Speciﬁcity
values were 90–99% for CE and 50–70% for PE. In all 5 coun-
tries, CE was cost saving when the prevalence of the disease was
10% or higher. Most common use for CE is at a prevalence of
50%. Cost savings at a prevalence of 50% are 1508€ (France),
1695€ (UK) and 2240€ (Switzerland). Probabilistic sensitivity
analyses approved a high robustness for these results. CON-
CLUSIONS: CE proved to have a higher effectiveness than PE
when diagnosing obscure bleeding. Though procedure costs vary
substantially from country to country, incremental analysis
shows that the use of CE has a cost-saving potential in all three
countries.
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OBJECTIVES: Assessing the potential increase in GERD medical
treatment expenses and the impact of on-demand treatment with
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esomeprazole. METHODS: The number of patients with GERD
was derived from epidemiological studies. The number of proton
pump inhibitor (PPI) users was calculated from IMS publications
and reimbursement data provided by sick-funds. According to
clinical practice, in future, the number of patients taking a PPI
will be the number of weekly GERD sufferers. Alternatively,
future PPI users will comprise patients currently receiving a PPI
plus those currently using H2-receptor antagonists, plus a large
part of current antacids users. Results of on-demand treatment
come from the ONE study (2-arm parallel study over a 6-month
maintenance period, on-demand versus continuous therapy with
esomeprazole 20mg). RESULTS: A totla of 28% of the Belgian
adult population (n = 10 million) have GERD symptom(s), 11%
weekly, 4% daily. Assuming stable prevalence of GERD over the
next decade, the number of PPI-treated patients could reach
approximately 920,000/year from 446,000 currently. Yearly
expenses would therefore increase from 149€ to 248€ million.
This would be reached by 2010 with linear growth or 2005 with
exponential growth. In 2652 Belgian patients with a similar
proﬁle to the screened population of the epidemiological studies,
the ONE study showed on-demand treatment (mean daily
intake: 0.6 tablet) was similar to continuous treatment (1
tablet/day) for patient satisfaction (92% in both groups), heart-
burn relapse (11.3% vs. 9.4%, respectively) and GERD-related
co-medication intake (8% vs. 7.3%, respectively). Over a 7-
month treatment period (4 weeks of acute treatment then 6
months’ maintenance), on-demand esomeprazole 20mg would
save approximately 27.5% on medication costs compared with
continuous esomeprazole therapy. CONCLUSIONS: Increasing
costs due to the expected increased use of PPI’s can be lowered
by using an effective PPI with an on-demand approach, which
maintains high patient satisfaction and efﬁcacy.
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OBJECTIVES: Gastro Esophageal Reﬂux Disease (GERD) is a
chronic condition that may affect patients’ quality of life. It is
one of the most common complaints in primary care settings
with relevant consequences on health economics in terms of
increasing health costs and limiting resources. An objective 
of this multicentre trial was to evaluate the time of action of
rabeprazole 20mg daily (RAB) and omeprazole 20mg daily
(OME) in inducing symptom relief in patients with reﬂux
oesophagitis in the curative phase. A prospective health eco-
nomic analysis was performed to compare the costs of the 2
treatments in obtaining symptoms improvement. METHODS: A
total of 484 patients, with mild to severe reﬂux oesophagitis
(Savary-Miller grade I to III), were randomised in a double-blind,
parallel group fashion, to receive RAB or OME for a period of
4 to 8 weeks with control visits every two weeks. The patients
had to ﬁll in a daily diary regarding to the number of tablets/cap-
sules taken, and the daytime and night time heartburn intensity
using the following score: absent, mild, moderate, severe and ter-
rible. The economic analysis was designed and carried out from
a societal and National Health Service perspective. RESULTS: In
the curative phase of reﬂux oesophagitis (4–8 weeks) treatment
with RAB (20mg) resulted less expensive than OME (20mg).
The estimated mean total costs were found to be lower in RAB
group (58.04€) than in the OME one (64.34€; p < 0.001). With
regard to numbers of symptom-free days, RAB (67.1%) was
found to be more effective than OME (66.8%). CONCLU-
SIONS: Rabeprazole (20mg) once daily is cost effective com-
pared with omeprazole (20mg) once daily in the curative phase
of reﬂux oesophagitis. Rabeprazole represents good value for
money and efﬁcient use of health care resources in the treatment
of reﬂux oesophagitis.
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OBJECTIVES: Endoscopic and laparoscopic surgeries are now
widely used to treat patients with stones in gallbladder and
common bile duct (CBD). The objectives of this study were to
compare the economic and clinical results between two methods
in the treatment of stones in gallbladder and CBD. METHODS:
A computer model was established to assess the cost-beneﬁt of
two types of treatment from the provider’s perspective. Treat-
ment A provided two-stage procedure, which performs endo-
scopic sphincterotomy (EST) ﬁrst and then followed by
laparoscopic cholecystectomy (LC) (EST + LC). Treatment B is
a one-stage procedure that performs laparoscopic surgery alone
to remove both the gallbladder and stones in common bile duct
(LCBDE + LC). Sources of parameters for the simulation model
came from the results of published articles and patients received
endoscopic and/or laparoscopic surgery in a medical center.
RESULTS: Treatment B had a better successful rate than that of
treatment A and a shorter length of hospital stay. However, treat-
ment A had better stone removal rate. Under current insurance
payment schedule, the net beneﬁt of treatment A is NT$ 16,816
and NT$ -11,603 for treatment B. Therefore, it will be cost-ben-
eﬁcial to do EST + LC under current payment schedule. Sensi-
tivity analysis showed that hospitals must reduce the cost of
LCBDE + LC to NT$ 44,500 to avoid loss (currently NT$
85,513). If the cost of LCBDE + LC can be reduced to 33,000,
it can achieve the same beneﬁt as EST + LC. CONCLUSIONS:
Providers should hold the therapy of EST + LC to be the major
treatment under current insurance payment schedule. LCBDE +
LC is not commonly performed in Taiwan because of insufﬁcient
payment. However, it has the advantage of reducing patients’
suffering, shorter operation waiting time, and shorter hospital
stay. It would be beneﬁcial to patients if hospitals can reduce the
cost of LCBDE + LC and perform the procedure when appro-
priate.
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OBJECTIVES: There have been only a few studies published in
the world literature to date dealing with the pharmacoeconom-
ics of Crohnxs disease including east and central European coun-
tries. METHODS: The retrospective cost of illness study was
carried out by the analysis of all medical records and by special
questionnaire of patients suffering from Crohnxs disease in
1999–2000. RESULTS: Of 54 patients, 30 women, and 24 men,
with the average age of 48.8 years and with the average dura-
tion of illness of 75.8 months, were divided into 3 subgroups
from the point of view of pharmacoeconomics: A,—uncompli-
cated, 24 persons, B,—with chronic corticosteroid treatment, 12
